Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G. Ascierto PA, et al. Among authors: richtig e. Nat Commun. 2024 Jan 2;15(1):146. doi: 10.1038/s41467-023-44475-6. Nat Commun. 2024. PMID: 38167503 Free PMC article. Clinical Trial.
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study.
Zager JS, Orloff M, Ferrucci PF, Choi J, Eschelman DJ, Glazer ES, Ejaz A, Howard JH, Richtig E, Ochsenreither S, Reddy SA, Lowe MC, Beasley GM, Gesierich A, Bender A, Gschnell M, Dummer R, Rivoire M, Arance A, Fenwick SW, Sacco JJ, Haferkamp S, Weishaupt C, John J, Wheater M, Ottensmeier CH. Zager JS, et al. Among authors: richtig e. Ann Surg Oncol. 2024 May 4. doi: 10.1245/s10434-024-15293-x. Online ahead of print. Ann Surg Oncol. 2024. PMID: 38704501
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
New ways to strengthen old risk factors.
Richtig G, Richtig E. Richtig G, et al. Among authors: richtig e. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):13-14. doi: 10.1111/jdv.19585. J Eur Acad Dermatol Venereol. 2024. PMID: 38126689 No abstract available.
Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter cohort study.
Barth DA, Moik F, Steinlechner S, Posch F, Mayer MC, Sandner AM, Berton F, Schlintl V, Koch L, John N, Wurm R, Pichler M, Bauernhofer T, Reimann P, Wohlkönig C, Richtig E, Winder T, Preusser M, Jost PJ, Ay C, Gerger A, Terbuch A, Riedl JM. Barth DA, et al. Among authors: richtig e. J Immunother Cancer. 2023 Dec 14;11(12):e007765. doi: 10.1136/jitc-2023-007765. J Immunother Cancer. 2023. PMID: 38097343 Free PMC article.
Dabrafenib plus trametinib in unselected advanced BRAF V600-mut melanoma: a non-interventional, multicenter, prospective trial.
Richtig E, Nguyen VA, Koelblinger P, Wolf I, Kehrer H, Saxinger W, Ressler JM, Weinlich G, Meyersburg D, Hafner C, Jecel-Grill E, Kofler J, Lange-Asschenfeldt B, Weihsengruber F, Rappersberger K, Svastics N, Gasser K, Seeber A, Kratochvill F, Nagler S, Mraz B, Hoeller C. Richtig E, et al. Melanoma Res. 2024 Apr 1;34(2):142-151. doi: 10.1097/CMR.0000000000000948. Epub 2023 Dec 13. Melanoma Res. 2024. PMID: 38092013 Free PMC article.
[Verwendung und Nutzen des Internets als Informationsquelle für Erkrankungen und Therapien in der Dermatologie: Usage and benefit of the Internet as a source of information on disease and therapy in dermatology].
Grossschaedl K, Vallant C, Dernoscheg MT, Richtig M, Öllinger A, Balakirski G, Wilsmann-Theis D, Nguyen VA, Weinlich G, Tsiogka A, Koelblinger P, Scheffel J, Richtig E, Richtig G. Grossschaedl K, et al. Among authors: richtig e. J Dtsch Dermatol Ges. 2023 Nov;21(11):1383-1386. doi: 10.1111/ddg.15199_g. Epub 2023 Oct 9. J Dtsch Dermatol Ges. 2023. PMID: 37811740 German. No abstract available.
Usage and benefit of the Internet as a source of information on disease and therapy in dermatology.
Grossschaedl K, Vallant C, Dernoscheg MT, Richtig M, Öllinger A, Balakirski G, Wilsmann-Theis D, Nguyen VA, Weinlich G, Tsiogka A, Koelblinger P, Scheffel J, Richtig E, Richtig G. Grossschaedl K, et al. Among authors: richtig e. J Dtsch Dermatol Ges. 2023 Nov;21(11):1383-1386. doi: 10.1111/ddg.15199. Epub 2023 Oct 9. J Dtsch Dermatol Ges. 2023. PMID: 37811739 No abstract available.
Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types.
Robinson I, Hochmair MJ, Schmidinger M, Absenger G, Pichler M, Nguyen VA, Richtig E, Rainer BM, Ay L, Jansen C, Pacífico C, Knabl A, Sladek B, Gasche N, Valipour A. Robinson I, et al. Among authors: richtig e. Cancers (Basel). 2023 Jun 21;15(13):3268. doi: 10.3390/cancers15133268. Cancers (Basel). 2023. PMID: 37444378 Free PMC article.
139 results